November 26, 2019 – New York, NY – The Lupus Research Alliance (LRA) 2019 Breaking Through Gala gathered more than 600 members of the global lupus community last night to raise $3 million, all of which goes directly to lupus research. The theme, Breaking Through, celebrates the many research discoveries that LRA makes possible to […] READ MORE
NEW YORK, NY – November 11. The Lupus Research Alliance (LRA) congratulates AstraZeneca on new positive results from the Phase 3 TULIP-2 trial (Treatment of Uncontrolled Lupus via the Interferon Pathway) presented at the 2019 ACR/ARP Annual Meeting. The data showed that the investigational biologic treatment anifrolumab significantly reduced disease activity for people with lupus. […] READ MORE
NEW YORK, Nov. 10, 2019 /PRNewswire/ — The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by Genentech at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting showing the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for the most severe […] READ MORE
Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […] READ MORE
NEW YORK, October 24 — The Lupus Research Alliance proudly announces two exceptional recipients of the 2019 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD. The highly prestigious up-to-$1 million grant will allow each investigator to test promising approaches for potential new lupus treatments. Dr. Mackay […] READ MORE
NEW YORK, NY. October 16 — The Lupus Research Alliance (LRA) is pleased to announce that seasoned professional Penny Mitchell has joined the organization as Senior Director of Marketing and Communications. In her new role, Ms. Mitchell will oversee the organization’s strategic communications approach to leading lupus research worldwide and the value of participation by […] READ MORE
NEW YORK, NY. August 29 — The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. Over 15 studies […] READ MORE
New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors. Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […] READ MORE
New York, NY– June 27, 2019. The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] READ MORE
NEW YORK, NY. June 19, 2019. The U.S. House of Representatives today passed the Fiscal Year 2020 Defense Appropriations Act, which allocates the Lupus Research Alliance advocate’s full request for $10 million — double the current budget — for the Lupus Research Program in the Department of Defense’s (DoD) Congressionally Directed Medical Research Program. The […] READ MORE
Boston, MA. June 19, 2019. The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients […] READ MORE
MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019. Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] READ MORE
